CD274 and astrocytoma (excluding glioblastoma): In this study, two of the three patients with astrocytoma who had prolonged SD with avelumab had high PD-L1+ tumours (≥ 80%); the other three patients with PD-L1+ tumours had PD as best response to avelumab.